Phase II study of dersalazine versus placebo and mesalazine in mild to moderate active ulcerative colitis

Phase 2, randomised, double-blind trial of Salcrozine in autoimmune colitis (3 arms), sponsored by Palau Pharma. Primary endpoint: Severe adverse events or adverse events leading to treatment withdrawal. Started Jul 2008; status: completed.